CN103301412A - Traditional Chinese medicine composition for treating alcoholic liver - Google Patents
Traditional Chinese medicine composition for treating alcoholic liver Download PDFInfo
- Publication number
- CN103301412A CN103301412A CN201310281640XA CN201310281640A CN103301412A CN 103301412 A CN103301412 A CN 103301412A CN 201310281640X A CN201310281640X A CN 201310281640XA CN 201310281640 A CN201310281640 A CN 201310281640A CN 103301412 A CN103301412 A CN 103301412A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- liver
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 86
- 210000004185 liver Anatomy 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 29
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- 208000010706 fatty liver disease Diseases 0.000 claims description 19
- 239000012567 medical material Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 210000000582 semen Anatomy 0.000 claims description 15
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 12
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims description 12
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 10
- 241000180649 Panax notoginseng Species 0.000 claims description 10
- 241000207929 Scutellaria Species 0.000 claims description 9
- 235000014375 Curcuma Nutrition 0.000 claims description 8
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 8
- 230000006837 decompression Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 241001522129 Pinellia Species 0.000 claims description 5
- 241000219780 Pueraria Species 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 3
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 244000164439 Curcuma angustifolia Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 239000000126 substance Substances 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 235000008658 Artemisia capillaris Nutrition 0.000 abstract 1
- 241000092668 Artemisia capillaris Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 241001521901 Tribulus lanuginosus Species 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 201000010099 disease Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 210000002784 stomach Anatomy 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 17
- 206010062717 Increased upper airway secretion Diseases 0.000 description 15
- 208000026435 phlegm Diseases 0.000 description 15
- 206010023126 Jaundice Diseases 0.000 description 14
- 230000035622 drinking Effects 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 241000407170 Curcuma Species 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 7
- 210000000232 gallbladder Anatomy 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000013334 alcoholic beverage Nutrition 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 108700022737 rat Fat1 Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010041519 Spider naevus Diseases 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003055 low molecular weight heparin Chemical group 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 150000004291 polyenes Chemical class 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229950000628 silibinin Drugs 0.000 description 2
- 235000014899 silybin Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000331777 Arisaema balansae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000112598 Pseudoblennius percoides Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229940019334 heparin group antithrombotic drug Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000010243 sho-seiryu-to Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating an alcoholic liver, and relates to the technical field of the traditional Chinese medicine. Aiming at the defects that overall effective treatment is in shortage on an alcoholic liver disease at present while recurrence is easily generated in chemical treatment, and the curative effect cannot last in the prior art, the invention provides the traditional Chinese medicine composition for treating the alcoholic liver. The traditional Chinese medicine composition is prepared from the following materials in parts by weight: 10 parts of rhizoma alismatis, 15 parts of peach kernel, 6 parts of capillary artemisia,10 parts of pseudo-ginseng, 10 parts of ligusticum wallichii, 6 parts of root of red-rooted salvia, 20 parts of fructus aurantii, 20 parts of hawthorn, 10 parts of radix bupleuri, 12 parts of radix curcumae, 15 parts of scutellaria baicalensis, 30 parts of tribulusterrestris, 6 parts of polygonum cuspidatum and 10 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention has a good treatment effect in the aspect of treatment of the alcoholic liver disease, and has significant clinical popularization value.
Description
Technical field
The invention belongs to the Chinese medicine technical field, be specifically related to a kind of Chinese medicine composition for the treatment of alcoholic liver.
Background technology
Alcoholic liver is a kind of commonly encountered diseases of modern society, and long-term excessive drinking can make hepatocyte that steatosis, necrosis and regeneration take place repeatedly by ethanol itself and its derivant acetaldehyde, causes alcoholic liver disease, comprises alcoholic fatty liver, wine
Smart hepatitis, hepatic fibrosis and liver cirrhosis.The early stage general no specific symptom of alcoholic liver and sign along with the development of the state of an illness, the indication of some digestive system and hepatopathy occurs, can cause alcoholic hepatitis, hepatic fibrosis gradually and liver cirrhosis takes place.Abdominal distention, weak, uncomfortable liver area, anorexia can appear in light disease, also have that jaundice, hepatomegaly and tenderness, complexion are gloomy, ascites, edema, spider angioma, heating, leukocytosis (therefore main be neutrophilic leukocytosis).If it is serious that the alcoholic liver sustainable development becomes, symptom of digestive tract can be apparent in view, have nauseating, vomiting, loss of appetite, weak, become thin, different symptoms such as the hepatic region is painful, severe patient is acute severe hepatitis or hepatic failure.Therefore, prevention and alleviation of alcohol liver have very important meaning.
Alcoholic fatty liver is because the hepatic disease that long-term heavy drinking causes is a typing in the alcoholic liver disease.The factor that influences the alcoholic liver injury progress or increase the weight of is more, and the risk factor that research both at home and abroad at present has been found that mainly comprises: drinking amount, the time limit of drinking, alcoholic beverage kind, the mode of drinking, sex, race, obesity, hepatites virus infections, inherited genetic factors, nutriture etc.According to the Epidemiological study data, the hepatic injury that ethanol causes has threshold effect, namely reaches certain drinking amount or the time limit of drinking, and will increase the hepatic injury risk greatly.Yet, because individual variation is bigger, also have to studies show that the dose-effect relationship of drinking with hepatic injury is very not clear and definite.The alcoholic beverage kind is more, and different alcoholic beverage is also variant to the infringement that liver causes.The mode of drinking also is a risk factor of alcoholic liver injury, drinks on an empty stomach and to cause hepatic injury with the mode of drinking of having meal is easier.The women is more responsive to the liver toxicity of ethanol mediation, compares with the male, and the more low dose of and shorter time limit of drinking just heavier alcoholic liver disease may occur.Drink the alcoholic beverage of isodose, alcohol water shows variant dawn in men and women's blood.
Alcoholic liver disease clinical diagnosis standard: 1. long-term history of drinking history is arranged, generally surpass 5 years, amount to amount of alcohol male 〉=40g/d, women 〉=20 g/d, or the heavy drinking history was arranged in 2 weeks, and amount to amount of alcohol〉80 g/dt.But should note sex, the influence of factors such as genetic predisposition.Amount of alcohol (g) reduction formula=drinking amount (m1) X ethanol content (%) * 0.8.
2. clinical symptoms is non-specific, can be asymptomatic, or have upper right abdominal distention and pain, inappetence, weak, the body constitution amount alleviates, jaundice etc.; Along with the state of an illness increases the weight of, neural mental symptom and performances such as spider angioma, liver palm can be arranged.
3. serum aspartate aminotransferase (AST), alanine aminotransferase (AL.T), γ one glutamyl transpeptidase (GGT), total bilirubin (TBil), prothrombin time (PT), mean corpuscular volume (MCV) and scarce sugared transferrins indexs such as (CDT) raise.AST/ALT wherein〉2, GGT raises, MCV raises and is the characteristics of alcoholic liver disease, though and the more special clinical not routine of CDT mensuration is carried out.These indexs of alcohol prohibition back can obviously descend, and common 4 all interior basic recover normal (but the GGT recovery is slower) help to diagnose.
4. liver B ultrasonic or CT examination have typical case's performance.
5. get rid of and have a liking for the existing disease infection of hepatovirus and medicine, toxic liver injury and autoimmune liver disease etc.
Meet the 1st, 2,3 and the 5th or the 1st, 2,4 and the 5th diagnosable alcoholic liver disease; Only meet l, 2 and the 5th the suspicious alcoholic liver disease of examining.
The proper prophylactic methods of alcoholic fatty liver is alleviating alcohol addiction, perhaps controls drinking amount, drinks low wine or soft drink as far as possible.Have more alcoholic liver prevention and health care product in the market, but the brand of health product is various, treatment mechanism is unclear, and curative effect is difficult to determine.The alcohol fatty hepatopath needs good nutritional support in addition, should provide high protein on the basis of alleviating alcohol addiction, low fat diet, and note vitimin supplement B, vitamin C, vitamin K and folic acid etc.Drug therapy remains the main means for the treatment of alcoholic liver.Slightly raise as Serum ALT, AST or GGT, can in time carry out Drug therapy, deterioration wards off disease.The treatment of S-ademetionine can improve alcohol fatty hepatopath's clinical symptoms and biochemical index.Polyene phosphatidylcholine has the trend that prevents that the histology from worsening to the alcohol fatty hepatopath.The glycyrrhizic acid preparation, medicines such as silymarin-group, polyene phosphatidylcholine and reduced glutathion have antioxidation in various degree, effects such as antiinflammatory, protection liver plasma membrane and organelle, clinical practice can improve the liver biochemical index.But these medicines exist the treatment target spot single in therapeutic process, long-term prescription occurs problem such as toleration easily and is difficult to alcoholic liver disease is reached comprehensive continued treatment effect, therefore seeks a kind of medicine of alcoholic liver safely and effectively and has very great social significance and economic implications.
Chinese medicine alcoholic fatty liver historical of long standing and well established, and as an importance of modern hepatopathy Comprehensive Treatment, more and more receive publicity in recent years.People seek single pharmaceutically active ingredient from traditional Chinese herbal medicine or compound recipe is treated cancer tool challenge.Make a general survey of the research direction of world's new drug, mainly be single chemicals and preparations thereof of research and development the eighties in the past, begins to develop biotechnology and natural medicinal plants after the eighties, and the drug research direction is tending towards multiformity.In conjunction with the modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened the preparation that extraction and/or compatibility make, its side effect is little, and is safe, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
The traditional Chinese medical science is familiar with very early the harm of excessive drinking, and the name of " alcoholic jaundice " is just arranged in its classical works " Medical Treasures of the Golden Chamber-jaundice abnormal pulse card is also controlled ".Have later on " teenager on the scoop, become more dropsy ", " alcoholic jaundice because of, its people is thing with wine.Or the time great drink, drunk deeply when the wind entry, hold concurrently with the long-pending heat of fat meat and fine grain, then the card of alcoholic jaundice becomes "; " wet from interior survivor, must its people's fat meat and fine grain wine sweet wine excessive." wait many argumentations.Debate disease and the dialectical research and development that combines according to the traditional Chinese medical science in recent years, the traditional Chinese medical science thinks that the main pathogenesis of alcoholic liver disease is that endogenous dampness is trouble, accumulates in the cold-damp or the damp-stagnancy heat-transformation at present, further to insufficiency of the spleen stagnation of liver-QI, the liver failing to maintain the normal flow of QI, qi stagnation blood stasis, finally cause liver, spleen, functions such as kidney are not normal and depleted.Clinically, the traditional Chinese medical science roughly is divided into turbid damp obstructing in middle-JIAO according to pathogenesis evolution characteristics and the determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs principle in this disease different lesions stage, damp-heat accumulation, cold-damp disturbing the spleen, stagnation of liver-QI with deficiency of the spleen, pattern of syndrome such as deficiecny of liver-YIN, adopt respectively dehumidifying and in, clearing away heat-damp and promoting diuresis, warming middle-JIAO for eliminating dampness, soothing liver and strengthening spleen removing dampness, blood circulation promoting and blood stasis dispelling, the yin nourishing easing the affected liver is etc. the method treatment, as dialectical accurate, medication is proper, still can obtain good effect.
Still there is not Drug therapy very comprehensively and effectively at present alcoholic liver, first purpose of the present invention is to provide a kind of Chinese medicine composition of alcoholic liver, and this Chinese medicine composition has good active anticancer aspect the diseases such as the damage for the treatment of ethanol, alcoholic fatty liver.Chinese medicine composition of the present invention is made by the raw material of following weight portion: 10 parts of Rhizoma Alismatis, 15 parts in Semen Persicae, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 6 parts of Radix Salviae Miltiorrhizaes, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Radix Curcumaes, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 6 parts of Rhizoma Polygoni Cuspidati, 10 parts in Radix Glycyrrhizae.
Rhizoma Alismatis (rhizome) is again one of traditional Chinese medicine.Theory of Chinese medical science thinks that it is cold in nature, has the effect of promoting diuresis to eliminate damp pathogen; Cure mainly expel the heat-evil treating stranguria, dysuria, the puckery pain of pyretic stranguria, edema distension, have loose bowels, disease such as dizziness due to fluid-retention.Modern medicine study, Rhizoma Alismatis can reduce serum total cholesterol and triacylglycerol content, slow down atherosclerosis and form; Rhizoma Alismatis and preparation modern times thereof also are used for the treatment of auditory vertigo, dyslipidemia, seminal emission, fatty liver and diabetes etc.
Semen Persicae has blood circulation promoting and blood stasis dispelling, loosening bowel to relieve constipation, the effect of relieving cough and asthma.Clinical in amenorrhea, dysmenorrhea ， WEIJIA mass in the abdomen, injury from falling down, diseases such as dryness of the intestine constipation.Be rich in the number of chemical composition in the Semen Persicae, be rich in amygdaloside, emulsin, volatile oil, fatty oil, mainly contain olein and a small amount of glyceryl linoleate in the oil.Modern pharmacology studies show that the Semen Persicae extracting solution is the cerebral blood flow increasing amount obviously, increases the blood flow of dog femoral artery, reduces vascular resistance, improves hemodynamic situation.Extract can improve the liver surface microcirculation of animal, and promotes bile secretion.Semen Persicae can make the hemorrhage and clotting time of mice obviously prolong, and decoct has inhibitory action to external thrombus, and decocting liquid has the fiber facilitation.Contain 45% fatty oil Castor Oil intestinal in the Semen Persicae, be beneficial to defecation.Semen Persicae can promote primipara's uterine contraction and hemorrhage.Water decoction and extract have analgesia, antiinflammatory, antibiotic, anti-allergic effects.Amygdaloside in the Semen Persicae has the effect of antitussive and antiasthmatic and anti-hepatic fibrosis.
Herba Artemisiae Scopariae has the effect of clearing away heat-damp and promoting diuresis, jaundice eliminating, cures mainly diseases such as jaundice, dysuria, eczema pruritus, infectious jaundice type hepatitis.Modern pharmacology research Herba Artemisiae Scopariae has function of gallbladder promoting, effects such as liver function protecting, analgesic, antiinflammatory, blood fat reducing, blood pressure lowering, coronary dilating.
Radix Notoginseng has removing stasis to stop bleeding, the effect of promoting blood circulation and detumescence analgesic therapy; The hot temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go diffusing, the up top, mountain peak that reaches; Go into blood system again, the descending sea of blood that reaches.The blood circulation promoting and blood stasis dispelling effect is extensive, the suitable various diseases of stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control diseases such as wind syndrome of head headache, rheumatic arthralgia.
Radix Salviae Miltiorrhizae has another name called Radix Salviae Miltiorrhizae, Radix Salviae Miltiorrhizae, Arisaema balansae Engl. etc.Be the dicotyledon Labiatae, dry root and rhizome.Has promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, the effect of nourishing blood to tranquillize the mind.It is more that Radix Salviae Miltiorrhizae is used for anti-hepatic fibrosis treatment research in the modern pharmacology research.Its mechanism may for: 1. improve microcirculation in the liver, protect hepatocyte, alleviate the hepatocellular degeneration necrosis; 2. strengthen the phagocytosis of reticuloendothelial cell; 3. strengthen OA, improve fibrin and connect level, alleviate hepatocyte injury; 4. suppress lipid peroxide, reduce oxygen-derived free radicals to hepatocellular damage.Above mechanism can be protected hepatocyte, reduces hepatocyte injury, necrosis etc. to the stimulation of sternzellen, suppresses startup and the development of hepatic fibrosis; Collagen content obviously reduces in the liver, and urine HPP output raises, and points out this medicine can promote established collagen degradation, and the collagen of hypertrophy is hydrolyzed absorption again.
Fructus Aurantii nature and flavor hardship, acid, be slightly cold, return lung, spleen, liver, stomach, large intestine channel, function cures mainly diseases such as weight behind septum pectorale feeling of fullness, distending pain over the hypochondrium, accumulation of food in the stomach and intes tine due to indigestion, distension and fullness in the abdomen, the dysentery, proctoptosis, uterine prolapse.Fructus Crataegi does medicinal with fruit, slightly warm in nature, and sour in the mouth is sweet, goes into spleen, stomach, Liver Channel, and the function of promoting digestion and invigorating the stomach, activating blood circulation to dissipate blood stasis, convergence dysentery relieving is arranged.To the long-pending phlegm retention of meat, feeling of fullness acid regurgitation, dysentery hemorrhoidal hamorrhage, lumbago hernia, puerperal after-pains, lochiorrhea, children's's breast food stagnate etc., all effective in cure." herbal classic " cloud: sour in the mouth, air cooling, so see its can help digestion long-pending, clots absorbing blood, then gas is non-cold.Having stagnates then becomes dysentery, prolonged lochia, and holding in lunar part then is after-pains.Fructus Crataegi can go into the taste removing food stagnancy and stagnate, and stagnated blood looses.Radix Bupleuri cold nature, bitter in the mouth, suffering are returned Liver Channel, gallbladder meridian, have expelling pathogenic factors from the exterior and expel the heat-evil, dispersing the stagnated live-QI to relieve the stagnation of QI, the effect of elevate a turnable ladder yang-energy." Bencao Jingshu ": " Radix Bupleuri is the shaoyang channel medicine administered to bring out the cold.Stagnation of QI in main trusted subordinate's the intestines and stomach, diet gathers, and the cold and heat pathogen pushes away Chen Zhixin, and except dysphoria with smothery sensation person under the typhoid fever heart, foot-shaoyang gallbladder is also.Gallbladder is peace and quiet mansion, do not have the nothing of going out and go into, khan not, emetic should not be given, purgative being prohibited, it is through at half exterior and half interior, so method from conciliating, the genus of Herba Sidae Rhombifoliae soup is also.Its property liter and loosing occupies sun, looses heresy also so can reach table.Pathogens agglomerating is dysphoria with smothery sensation under the heart then, and the evil dysphoria with smothery sensation of loosing is then explained by oneself.Yang-energy sink, and then for diet gathers, sun rises that then clearing heat in QI system is up, the capable Yang Dao of QI of the spleen and stomach, and then diet gathers from dissipation.All expectorant accumulation of heats are real, and are evil contrary in the heart, faint breath person between the five internal organs, and the evil disease of viscera connecting with this channel of few YANG excess heat is also.Radix Bupleuri is bitter flat and be slightly cold, can the heat extraction eliminating stagnation and induce sweat, so all diseases more than healing.
Radix Curcumae, acrid in the mouth, hardship, cold in nature.Return liver, the heart, lung meridian, have the usefulness of regulating qi to disperse stagnation, heart fire-clearing upset-relieving, promoting the function of the gallbladder to alleviate jaundice, promoting blood circulation and stopping pain, promoting QI circulation for relieving depression, the removing heat from blood that clears away heart-fire.Record in " book on Chinese herbal medicine converges and says ": Radix Curcumae, clearing heat in QI system reduces phlegm, and the medicine of dissipating blood stasis blood is also.Its property lightly floats, the stasis of loosing, along contrary gas, on reach high mountain peak, the benefaction part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, cardiopulmonary liver gastric qi blood fire-phlegm is strongly fragrant holds back not that passerby tests most, so control breast stomach diaphragmodynia, two side of body distensions, the tripe abdomen is attacked painful, diet does not think to wait card.Control passages through which vital energy circulates again and drive in the wrong direction, hematemesis and epistaxis, hemoptysis is bloody.This medicine can sending down the abnormal ascending QI, and gas falls then that fire falls, and expectorant and blood also respectively follow it and pacifies part and return former.
Radix Scutellariae another name Radix Scutellariae, tsuchikane tea root are labiate, are used as medicine with root.Heat clearing and damp drying is arranged, and removing heat from blood is antiabortive, detoxicating functions.Cure mainly diseases such as epidemic febrile disease, upper respiratory tract infection, cough due to lung-heat, damp and hot jaundice, pneumonia, dysentery, hemoptysis, conjunctival congestion, frequent fetal movement, hypertension, carbuncle furuncle.Rhizoma Atractylodis have drying damp and strengthening spleen, expelling wind and cold, and the effect that makes eye bright is used for wet resistance taste, distension and fullness in the abdomen, the cold-damp leucorrhea, damp-warm diseases and damp invasion of lower energizer, foot swelling and pain in knee, flaccidity are soft unable.Controlling wet resistance taste, and seeing the thick disease such as turbid of distension and fullness in the abdomen, inappetence, fatigue and weakness, white and greasy fur, normal and compatibility application such as Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae.
The little hardship of Rhizoma Polygoni Cuspidati is slightly cold.Return liver, gallbladder, lung meridian.Function cures mainly heat-clearing and toxic substances removing, promoting the function of the gallbladder to alleviate jaundice, expelling wind and removing dampness, dissipating blood stasis analgesic therapy, diseases such as relieving cough and resolving phlegm.Be used for arthralgia, jaundice due to damp-heat, amenorrhea, postnatal blood stasis are not Xiaed the ， WEIJIA, cough with copious phlegm, burn due to hot liquid or fire, traumatic injury, carbuncle sore tumefacting virus.Use Rhizoma Polygoni Cuspidati, the Radix Aucklandiae, Fructus Aurantii, scutellaria dispensing treating the liver disease clinically.Modern medicine study shows that Rhizoma Polygoni Cuspidati contains knotweed glycoside, organic acid, glycoside, polysaccharide etc.Heat-clearing and toxic substances removing, cooling and heatstroke-eliminating, stomach invigorating food effect is clearly arranged.
Rhizoma Alismatis and Herba Artemisiae Scopariae can play dispelling phlegm and eliminating dampness, protect the liver jaundice eliminating.Radix Notoginseng, Rhizoma Chuanxiong blood circulation promoting and blood stasis dispelling, removing mass collateral dredging; Fructus Aurantii and Fructus Crataegi can promoting digestion and invigorating the stomach, eliminate the distension and fullness in the abdomen symptom.The tender enough heat clearing and damp drying of Radix Bupleuri and Radix Scutellariae, eliminating stagnation are induced sweat.Rhizoma Polygoni Cuspidati and Radix Salviae Miltiorrhizae can nourishing blood to suppress the hyperactive liver, nourishing blood to tranquillize the mind.The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.All medicines share, altogether the effect of long memorial liver resolving depression, spleen invigorating food stagnation removing, activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness.
As a kind of embodiment preferred for this invention, can also further comprise 10 parts of 8 parts of the Rhizoma Pinelliaes and Radix Puerariaes in the above-mentioned Chinese medicine composition raw material.Two kinds of medicines and above-mentioned Chinese medicine composition coupling can further strengthen the metabolism ability of liver, and can reduce medicine to the drug toxicity of body.The Rhizoma Pinelliae is a kind of important medical material in the Chinese medicine treasure-house, and the place of production has only the Chinese and Japanese of Asia.Its function is drying dampness to eliminate phlegm, and the stomach function regulating preventing or arresting vomiting cures mainly the phlegm-damp diseases caused by retention of fluid, vomiting, diseases such as cough with asthma.The hot warm-dryness syndrome that looses of this product is poisonous, mainly goes into that taste are double goes into lung, and the water of manage it wets, lowering the adverse flow of QI, and be apt to dispel the taste damp-phlegm.Water is wet to go then the strong and sputum of spleen from disappearing, contrary gas harmonization of the stomach falls then and the feeling of fullness vomiting from ending, so be drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI, the good medicine of dissolving lump and resolving mass.Both cured mainly the abundant expectoration cough with asthma QI rising in reverse order of spleen damp-phlegm heap soil or fertilizer over and around the roots, as ERCHEN TANG, XIAOQINGLONG TANG, controlled the dizzy palpitation and insomnia of violating on the damp-phlegm again, as banxia baizhu tianma decoction, also can control wind-phlegm tell contrary, headache limb fiber crops, hemiplegia, diseases such as facial hemiparalysis are as beautiful kettle ball.Radix Puerariae is as rare Chinese medicine, in the existing long history of more than one thousand years of China.Be the successive dynasties heat-clearing and toxic substances removing, promote blood circulation and sober up, breathe out the key medicine that liver is protected kidney.These are in Shennong's Herbal, recipes for Saving Lives, Compendium of Material Medica and " in tens documents and materials such as Chinese pharmacopoeia, clear and definite record is arranged.Radix Puerariae has relieving muscles diaphoresis, treating measles, analgesic promoting the production of body fluid, the effect of yang invigorating antidiarrheal.Be used for fever caused by exogenous pathogens headache, stiffness of the nape, thirsty, measles without adequate eruption, have loose bowels, disease such as hypertension neck pain.The modern study Radix Puerariae contains more than 20 kind of isoflavones components, Radix Puerariae glycoside, triterpenes, alkaloid and other active component, has multiple pharmacological effect.Total ketone in the Radix Puerariae can increase brain and blood flow coronarius.Radix Puerariae has obvious facilitation to the cerebral circulation of animal and human's body.Modern medicine and pharmacology studies show that: Radix Puerariae contains abundant puerarin, this glucoside of Xun Gensu, soybean isoflavone, daidzein, ammonia pours acid, trace element, triterpene substance alkali etc. to human body beneficial's important biomolecule active substance.Have nourishing the human Body, beauty care, slow down aging, improve osteoporosis, regulate estrogen level, remove rubbish in the body, and improve plurality of health care functions such as circulation, lowering blood-fat and reducing weight, adjusting blood pressure.Radix Puerariae improves hepatocellular regeneration capacity, recovers the normal liver function, promotes bile secretion, prevents that fat from piling up at liver.And can enhance metabolism, strengthen liver detoxification function, prevent that ethanol is to the damage of liver.
The method for preparing Chinese medicine composition of the present invention is as follows: get each medical material of above-mentioned components by weight percent, add the 5-15 water doubly of medical material gross weight, soaked 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, and this relative density is the testing result under 60 degrees centigrade, adds ethanol and is 60-90%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, reclaim ethanol to concentrating, namely.The above-mentioned Chinese medicine composition of the present invention can further be prepared into pharmaceutical preparation commonly used clinically, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, i.e. the purposes of above-mentioned Chinese medicine composition in preparation treatment or prevention alcoholic liver medicine.Wherein said alcoholic liver disease is alcoholic liver, alcoholic fatty liver, alcoholic hepatitis or the hepatic fibrosis or the liver cirrhosis that are caused by alcoholic liver.The present invention is by investigating Chinese medicine composition of the present invention to the treatment experiment of rat alcoholic fatty liver model, find that Chinese medicine composition provided by the invention can obviously reduce AST and the ALT of fatty liver rat model, TG, TC and the LDL-C of fatty rat model can be significantly reduced, and the liver index of rat model can be significantly reduced.This acts on comprehensively when showing Chinese medicine composition of the present invention to treatment or prevention fatty liver disease, has obvious synergism, has obtained unforeseeable curative effect of medication.Its therapeutic effect to fatty liver is better than existing medicine silibinin.
In a word, the present invention compared with prior art has the activity of fine treatment fatty liver, and can the present invention be pure Chinese medicinal preparation, to human body particularly to the liver avirulence.When the present invention used as the fatty liver medicine, drug effect was comprehensive, in dispersing the stagnated live-QI to relieve the stagnation of QI, spleen invigorating food stagnation removing, can also obtain the effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness, and sb.'s illness took a favorable turn can to make Patients with Fatty Liver rapidly; And Chinese medicine composition preparation of the present invention is simple, and nontoxic substantially, raw material is easy to get, and is suitable for popular use, has good application prospects.
The specific embodiment
Below further describe the present invention by the specific embodiment, but the present invention is not limited only to following examples.Within the scope of the invention or in not breaking away from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they all are regarded as comprising within the scope of the present invention.
First, the preparation of Chinese medicine composition of the present invention
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: 10 parts of Rhizoma Alismatis, 15 parts in Semen Persicae, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 6 parts of Radix Salviae Miltiorrhizaes, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Radix Curcumaes, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 6 parts of Rhizoma Polygoni Cuspidati, 10 parts in Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 5 times water of medical material gross weight, soaked 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 75%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, packing, flowing steam sterilization 35min namely gets mixture.
Embodiment 2 Chinese medicine composition tablets of the present invention
Prescription: 10 parts of Rhizoma Alismatis, 15 parts in Semen Persicae, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 6 parts of Radix Salviae Miltiorrhizaes, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Radix Curcumaes, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 6 parts of Rhizoma Polygoni Cuspidati, 10 parts in Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 10 times water of medical material gross weight, soaked 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.25, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 80%(v/v to containing the alcohol amount), left standstill 24 hours, and got supernatant, reclaim ethanol to concentrating, vacuum drying, granulation, tabletting are namely.
Embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: 10 parts of Rhizoma Alismatis, 15 parts in Semen Persicae, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 6 parts of Radix Salviae Miltiorrhizaes, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Radix Curcumaes, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 6 parts of Rhizoma Polygoni Cuspidati, 10 parts in Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 8 times water of medical material gross weight, soaked 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 90%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, reclaim ethanol to concentrating, vacuum drying is granulated, and is namely encapsulated.
Embodiment 4 Chinese medicine composition mixture of the present invention
Prescription: 10 parts of Rhizoma Alismatis, 15 parts in Semen Persicae, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 6 parts of Radix Salviae Miltiorrhizaes, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Radix Curcumaes, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 6 parts of Rhizoma Polygoni Cuspidati, 10 parts in Radix Glycyrrhizae, 8 parts of the Rhizoma Pinelliaes, 10 parts of Radix Puerariaes.
Preparation method: get each medical material of above-mentioned components by weight percent, add 5 times water of medical material gross weight, soaked 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 75%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, packing, flowing steam sterilization 35min namely gets mixture.
Embodiment 5 Chinese medicine composition tablets of the present invention
Prescription: 10 parts of Rhizoma Alismatis, 15 parts in Semen Persicae, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 6 parts of Radix Salviae Miltiorrhizaes, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Radix Curcumaes, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 6 parts of Rhizoma Polygoni Cuspidati, 10 parts in Radix Glycyrrhizae, 8 parts of the Rhizoma Pinelliaes, 10 parts of Radix Puerariaes.
Preparation method: get each medical material of above-mentioned components by weight percent, add 10 times water of medical material gross weight, soaked 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.25, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 80%(v/v to containing the alcohol amount), left standstill 24 hours, and got supernatant, reclaim ethanol to concentrating, vacuum drying, granulation, tabletting are namely.
Embodiment 6 Chinese medicinal composition capsules of the present invention
Prescription: 10 parts of Rhizoma Alismatis, 15 parts in Semen Persicae, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 6 parts of Radix Salviae Miltiorrhizaes, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Radix Curcumaes, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 6 parts of Rhizoma Polygoni Cuspidati, 10 parts in Radix Glycyrrhizae, 8 parts of the Rhizoma Pinelliaes, 10 parts of Radix Puerariaes.
Preparation method: get each medical material of above-mentioned components by weight percent, add 8 times water of medical material gross weight, soaked 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 90%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, reclaim ethanol to concentrating, vacuum drying is granulated, and is namely encapsulated.
Second portion, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
Embodiment 7 Chinese medicine compositions of the present invention are to the treatment of non-alcoholic fatty liver disease
1, alcoholic fatty liver Preparation of model
Using body weight is the male SD rat of cleaning level healthy adult of 125～155 g, freely drink the drinks beverage that 55 ° of strong, colourless liquor distilled from sorghum Chinese liquor are mixed with variable concentrations and contain 10% white sugar, its Chinese liquor degree increases progressively gradually according to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40% (V/V), each concentration continues 10 days, kept for 20 weeks in 40% o'clock, in total 30 weeks of modeling time, make up alcoholic fatty liver pathology animal model.Each all gives ad lib full nutrition pellet during organizing rat experiment.
2, grouping and administration
After the rat model adaptability raised for 1 week, be divided into normal group, model group and administration group at random, specifically grouping situation sees the following form, 10 every group.Irritate the stomach medicine every afternoon during 14:30, and dosage is as follows:
The normal control group: the filling stomach gives the distilled water with volume;
Model control group: the filling stomach gives the distilled water with volume;
Silibinin group: irritate stomach and give 25mg/(kg.d) silibinin;
Low dose group: irritate stomach and give the embodiment of the invention 1 prepared Chinese medicine composition mixture, crude drug dosage 0.1 g/(kg.d);
Middle dosage group: irritate stomach and give the embodiment of the invention 1 prepared Chinese medicine composition mixture, crude drug dosage 1 g/(kg.d);
High dose group: irritate stomach and give the embodiment of the invention 1 prepared Chinese medicine composition mixture, crude drug dosage 10 g/(kg.d);
3, detect index
After the last administration, the pentobarbital sodium anesthetized rat is dissected, and the abdomen cardinal vein is got the hematometry biochemical indicator, gets liver and weighs.
3.1. liver function
Result of the test shows (seeing table 1 for details), alcoholic fatty liver model group rat blood serum ALT, AST content are compared with normal group significantly and are raise, the rat blood serum ALT of each administration group, AST content are compared obvious decline with model group, especially, each dosage group of compound recipe is compared with model group has utmost point significant difference, compared utmost point significant difference with the silibinin group, each Chinese medicine of this explanation Chinese medicine composition of the present invention has been obtained synergitic effect in prevention or treatment to the rat fat liver.
Table 1 Chinese medicine composition of the present invention is to the influence of rat model liver function
Compare with model group,
*P＜0.05; Compare with model group,
*P＜0.01;
Compare with the silibinin group,
#P＜0.05; Compare with the silibinin group,
##P＜0.01.
3.2 blood fat
Result of the test shows (seeing table 2 for details), the level of T-CHOL, triglyceride, HDL-C and the low-density lipoprotein cholesterol of each dosage group of compound recipe has been compared significant difference or utmost point significant difference with rat fat liver model group, compare with silibinin group or low molecular weight heparin group and also to have significant difference or utmost point significant difference (except the hdl level), Chinese medicine use in conjunction in this explanation Chinese medicine composition of the present invention, on rat fat liver model, obtained good synergism at reduction TG, TC and LDL-C.
Table 2 Chinese medicine composition of the present invention is to the influence of rat model blood fat
Compare with model group,
*P＜0.05; Compare with model group,
*P＜0.01;
Compare with the silibinin group,
#P＜0.05; Compare with the silibinin group,
##P＜0.01.
3.3. liver index
Result of the test shows (seeing table 3 for details), alcoholic fatty liver model group rats'liver index has been compared utmost point significant difference with normal group, the liver index of the rat of each administration group has been compared utmost point significant difference with model group, especially, each dosage group of compound recipe has been compared significant difference or utmost point significant difference with pyrrole group or Low molecular heparin group, each Chinese medicine of this explanation Chinese medicine composition of the present invention has been obtained good synergism in this index of reduction liver index on rat fat liver model.
Table 3 Chinese medicine composition of the present invention is to the influence of Rats Organs and Tissues index
Compare with normal group,
$P＜0.05; Compare with normal group,
$$P＜0.01;
Compare with model group,
*P＜0.05; Compare with model group,
*P＜0.01;
Compare with the silibinin group,
#P＜0.05; Compare with the silibinin group,
##P＜0.01.
Claims (6)
1. Chinese medicine composition for the treatment of alcoholic liver, it is characterized in that being made by the raw material of following weight portion: 10 parts of Rhizoma Alismatis, 15 parts in Semen Persicae, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 6 parts of Radix Salviae Miltiorrhizaes, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 12 parts of Radix Curcumaes, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 6 parts of Rhizoma Polygoni Cuspidati, 10 parts in Radix Glycyrrhizae.
2. the Chinese medicine composition for the treatment of alcoholic liver as claimed in claim 1 is characterized in that: also contain 10 parts of 8 parts of the Rhizoma Pinelliaes and Radix Puerariaes in the described Chinese medicine composition raw material.
3. the Chinese medicine composition for the treatment of alcoholic liver as claimed in claim 1 or 2, it is characterized in that: described Chinese medicine composition is mixture, tablet or capsule.
4. the preparation method of Chinese medicine composition as claimed in claim 1 or 2 is characterized in that may further comprise the steps: get each medical material, add the 5-15 water doubly of medical material gross weight, soaked 10-60 minute, and decocted 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, this relative density is the testing result under 60 degrees centigrade, add ethanol to containing the alcohol amount for 60-90%v/v, left standstill 24 hours, get supernatant, reclaim ethanol to concentrating, namely.
5. the Chinese medicine composition for the treatment of alcoholic liver as claimed in claim 1 or 2, the purposes in preparation treatment or prevention alcoholic liver medicine.
6. the Chinese medicine composition for the treatment of alcoholic liver as claimed in claim 5 is characterized in that: described alcoholic liver disease is alcoholic liver, alcoholic fatty liver, alcoholic hepatitis or the hepatic fibrosis or the liver cirrhosis that are caused by alcoholic liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310281640XA CN103301412A (en) | 2013-07-07 | 2013-07-07 | Traditional Chinese medicine composition for treating alcoholic liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310281640XA CN103301412A (en) | 2013-07-07 | 2013-07-07 | Traditional Chinese medicine composition for treating alcoholic liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103301412A true CN103301412A (en) | 2013-09-18 |
Family
ID=49127418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310281640XA Pending CN103301412A (en) | 2013-07-07 | 2013-07-07 | Traditional Chinese medicine composition for treating alcoholic liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103301412A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103493935A (en) * | 2013-10-15 | 2014-01-08 | 北京绿源求证科技发展有限责任公司 | Liver-nourishing food-made tea granules for preventing alcohol liver |
| CN103705731A (en) * | 2014-01-02 | 2014-04-09 | 王雪雁 | Traditional Chinese medicine composition for treating chronic alcoholic toxic liver disease |
| CN103784874A (en) * | 2013-12-20 | 2014-05-14 | 霍山县中医院 | Traditional Chinese medicinal composition for treating obesity fatty liver |
| CN103830337A (en) * | 2014-03-25 | 2014-06-04 | 崔新明 | Chinese medicinal composition for treating chronic alcoholic toxic liver disease |
| CN104127826A (en) * | 2014-08-12 | 2014-11-05 | 崔银方 | Traditional Chinese medicine composition for treating chronic alcoholic liver disease |
| CN104547911A (en) * | 2014-12-30 | 2015-04-29 | 朱惊涛 | Traditional Chinese medicine preparation for treating liver-stomach disharmony type alcoholic liver disease and preparation method |
| CN104958602A (en) * | 2015-07-16 | 2015-10-07 | 姜彩红 | Traditional Chinese medicine composition for treating alcoholic jaundice |
| CN104984255A (en) * | 2015-07-24 | 2015-10-21 | 徐冬冬 | Traditional Chinese medicine pill for auxiliary treatment on alcoholic fatty liver and preparation method thereof |
| CN105456633A (en) * | 2015-12-31 | 2016-04-06 | 青岛昌安达药业有限公司 | Traditional Chinese medicine composition for treating alcoholic liver disease |
| CN105561001A (en) * | 2016-01-29 | 2016-05-11 | 管迎春 | Traditional Chinese medicine composition for treating alcoholic hepatitis |
| CN105596899A (en) * | 2015-12-31 | 2016-05-25 | 青岛昌安达药业有限公司 | Traditional Chinese medicine decoction for treating alcoholic liver disease |
| CN107898972A (en) * | 2017-12-10 | 2018-04-13 | 王刚 | A kind of Chinese medicine composition and application for being used to treat liver diseases |
| CN109125623A (en) * | 2018-01-23 | 2019-01-04 | 刘媛媛 | It is a kind of for treating the pharmaceutical composition of hepatopathy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727686A (en) * | 2012-07-20 | 2012-10-17 | 杨献华 | Traditional Chinese medicine composition for treating fatty liver |
-
2013
- 2013-07-07 CN CN201310281640XA patent/CN103301412A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727686A (en) * | 2012-07-20 | 2012-10-17 | 杨献华 | Traditional Chinese medicine composition for treating fatty liver |
Non-Patent Citations (1)
| Title |
|---|
| 殷晓轩等: "酒精性肝病中医用药规律探讨", 《中国实验方剂学杂志》 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103493935A (en) * | 2013-10-15 | 2014-01-08 | 北京绿源求证科技发展有限责任公司 | Liver-nourishing food-made tea granules for preventing alcohol liver |
| CN103784874A (en) * | 2013-12-20 | 2014-05-14 | 霍山县中医院 | Traditional Chinese medicinal composition for treating obesity fatty liver |
| CN103705731B (en) * | 2014-01-02 | 2015-10-07 | 王雪雁 | A kind of Chinese medicine composition for the treatment of chronic alcoholic toxic liver disease |
| CN103705731A (en) * | 2014-01-02 | 2014-04-09 | 王雪雁 | Traditional Chinese medicine composition for treating chronic alcoholic toxic liver disease |
| CN103830337A (en) * | 2014-03-25 | 2014-06-04 | 崔新明 | Chinese medicinal composition for treating chronic alcoholic toxic liver disease |
| CN104127826A (en) * | 2014-08-12 | 2014-11-05 | 崔银方 | Traditional Chinese medicine composition for treating chronic alcoholic liver disease |
| CN104547911A (en) * | 2014-12-30 | 2015-04-29 | 朱惊涛 | Traditional Chinese medicine preparation for treating liver-stomach disharmony type alcoholic liver disease and preparation method |
| CN104958602A (en) * | 2015-07-16 | 2015-10-07 | 姜彩红 | Traditional Chinese medicine composition for treating alcoholic jaundice |
| CN104984255A (en) * | 2015-07-24 | 2015-10-21 | 徐冬冬 | Traditional Chinese medicine pill for auxiliary treatment on alcoholic fatty liver and preparation method thereof |
| CN105456633A (en) * | 2015-12-31 | 2016-04-06 | 青岛昌安达药业有限公司 | Traditional Chinese medicine composition for treating alcoholic liver disease |
| CN105596899A (en) * | 2015-12-31 | 2016-05-25 | 青岛昌安达药业有限公司 | Traditional Chinese medicine decoction for treating alcoholic liver disease |
| CN105561001A (en) * | 2016-01-29 | 2016-05-11 | 管迎春 | Traditional Chinese medicine composition for treating alcoholic hepatitis |
| CN107898972A (en) * | 2017-12-10 | 2018-04-13 | 王刚 | A kind of Chinese medicine composition and application for being used to treat liver diseases |
| CN109125623A (en) * | 2018-01-23 | 2019-01-04 | 刘媛媛 | It is a kind of for treating the pharmaceutical composition of hepatopathy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048933B (en) | Chinese medicinal composition for treating infantile diarrhea and preparation method thereof | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| CN101972338B (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
| CN103099959B (en) | Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof | |
| CN102698137B (en) | Composition with blood pressure reducing function and preparation method of same | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN105343625A (en) | Taraxacum oral liquid for expelling toxin, dehumidifying and benefiting gallbladder and preparation method thereof | |
| CN102727686A (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN103990081A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN103784802A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN103041256B (en) | Chinese herb preparation for curing recurrent respiratory tract infection of children | |
| CN102988675B (en) | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof | |
| CN103749819B (en) | Fructus Corni health protection tea of a kind of hypoglycemic and preparation method thereof | |
| CN103041257B (en) | Chinese materia medica preparation for curing high fever and respiratory tract infection of children | |
| CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN105497816A (en) | Traditional Chinese medicine preparation for treating atherosclerosis and preparation method thereof | |
| CN105194421A (en) | Self-heal health-care oral solution capable of reducing blood fat and preparation method thereof | |
| CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
| CN103041255B (en) | Chinese materia medica preparation for curing swollen sore throat and respiratory tract infection of children | |
| CN102671056B (en) | Chinese medicinal composition for treating hepatitis and preparation method thereof | |
| CN104784549A (en) | Traditional Chinese medicine for treating allergic rhinitis | |
| CN104083548A (en) | Traditional Chinese medicinal composition for treating ovarian cyst and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130918 |